|
CCN2 |
cellular communication network factor 2 |
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- RUNX3 regulates YAP1-mediated transcription
|
|
|
|
CD82 |
CD82 molecule |
|
|
|
|
CLU |
clusterin |
- Platelet degranulation
- Terminal pathway of complement
- Antimicrobial peptides
- Regulation of Complement cascade
|
- Zinc
- Copper
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
CTSG |
cathepsin G |
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Metabolism of Angiotensinogen to Angiotensins
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Interleukin-1 processing
- Neutrophil degranulation
- Antimicrobial peptides
- Suppression of apoptosis
- Purinergic signaling in leishmaniasis infection
|
- Bis-Napthyl Beta-Ketophosphonic Acid
- 2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid
|
|
|
DAB1 |
DAB adaptor protein 1 |
- Reelin signalling pathway
|
|
|
|
DAB2 |
DAB adaptor protein 2 |
- Gap junction degradation
- Formation of annular gap junctions
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
|
|
DLG4 |
discs large MAGUK scaffold protein 4 |
- Signaling by ERBB4
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- NrCAM interactions
- Activation of Ca-permeable Kainate Receptor
- RHO GTPases activate CIT
- RAF/MAP kinase cascade
- LGI-ADAM interactions
- Neurexins and neuroligins
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Guanidine
- Guanosine-5'-Monophosphate
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Respiratory syncytial virus (RSV) attachment and entry
- Developmental Lineage of Mammary Gland Myoepithelial Cells
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Poziotinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
- Mobocertinib
- Almonertinib
- Amivantamab
|
- Laryngeal cancer
- Cervical cancer
- Oral cancer
- Gastric cancer
- Choriocarcinoma
- Esophageal cancer
- Glioma
- Bladder cancer
|
|
ELANE |
elastase, neutrophil expressed |
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Pyroptosis
- Neutrophil degranulation
- Antimicrobial peptides
- Regulation of Complement cascade
- Expression of NOTCH2NL genes
|
- Alpha-1-proteinase inhibitor
- Mdl 101,146
- Freselestat
- Elafin
- Lupeol
- Ursolic acid
|
- Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia
|
|
F8 |
coagulation factor VIII |
- Platelet degranulation
- Intrinsic Pathway of Fibrin Clot Formation
- Common Pathway of Fibrin Clot Formation
- Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
- COPII-mediated vesicle transport
- Cargo concentration in the ER
- Defective factor IX causes thrombophilia
- Defective F8 accelerates dissociation of the A2 domain
- Defective F8 cleavage by thrombin
- Defective F8 binding to von Willebrand factor
- Defective F8 binding to the cell membrane
- Defective cofactor function of FVIIIa variant
- Defective F8 secretion
- Defective F9 variant does not activate FX
- Defective F8 sulfation at Y1699
|
- Drotrecogin alfa
- Coagulation Factor IX (Recombinant)
- TB-402
- Thrombin
- Protein C
- Human thrombin
- Thrombin alfa
- Vonicog alfa
- Von Willebrand factor human
- Anti-inhibitor coagulant complex
- Coagulation Factor IX Human
- Nonacog beta pegol
- Damoctocog alfa pegol
- Rurioctocog alfa pegol
|
- Hemophilia; Hemophilia A (HEMA); Hemophilia B (HEMB); von Willebrand disease (VWD)
|
|
F9 |
coagulation factor IX |
- Extrinsic Pathway of Fibrin Clot Formation
- Intrinsic Pathway of Fibrin Clot Formation
- Gamma-carboxylation of protein precursors
- Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
- Removal of aminoterminal propeptides from gamma-carboxylated proteins
- Protein hydroxylation
- Defective factor IX causes thrombophilia
- Defective cofactor function of FVIIIa variant
- Defective F9 variant does not activate FX
- Defective F9 secretion
- Defective F9 activation
- Defective gamma-carboxylation of F9
|
- Antihemophilic factor, human recombinant
- Menadione
- TTP889
- Turoctocog alfa
- Kappadione
- Coagulation factor VII human
- Antihemophilic factor human
- Emicizumab
- Lonoctocog alfa
- Moroctocog alfa
- Turoctocog alfa pegol
|
- Hemophilia; Hemophilia A (HEMA); Hemophilia B (HEMB); von Willebrand disease (VWD)
|
|
FURIN |
furin, paired basic amino acid cleaving enzyme |
- Signaling by NODAL
- Collagen degradation
- Collagen degradation
- Elastic fibre formation
- Activation of Matrix Metalloproteinases
- Removal of aminoterminal propeptides from gamma-carboxylated proteins
- NGF processing
- Synthesis and processing of ENV and VPU
- Signaling by PDGF
- Pre-NOTCH Processing in Golgi
- TGF-beta receptor signaling activates SMADs
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Uptake and function of anthrax toxins
- Formation of the cornified envelope
- Assembly of active LPL and LIPC lipase complexes
- CD163 mediating an anti-inflammatory response
- Potential therapeutics for SARS
- Attachment and Entry
- Induction of Cell-Cell Fusion
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
- Amyloid fiber formation
- Respiratory syncytial virus (RSV) attachment and entry
- Maturation of hRSV A proteins
|
|
|
|
GIPC1 |
GIPC PDZ domain containing family member 1 |
- FGFR1b ligand binding and activation
- FGFR1c ligand binding and activation
- TGFBR3 regulates TGF-beta signaling
- TGFBR3 regulates FGF2 signaling
|
|
|
|
GTPBP1 |
GTP binding protein 1 |
|
|
|
|
GULP1 |
GULP PTB domain containing engulfment adaptor 1 |
|
|
|
|
HNRNPDL |
heterogeneous nuclear ribonucleoprotein D like |
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
|
|
|
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- DDX58/IFIH1-mediated induction of interferon-alpha/beta
- vRNP Assembly
- Regulation of actin dynamics for phagocytic cup formation
- eNOS activation
- Regulation of PLK1 Activity at G2/M Transition
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Sema3A PAK dependent Axon repulsion
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Anchoring of the basal body to the plasma membrane
- Constitutive Signaling by EGFRvIII
- Regulation of necroptotic cell death
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Downregulation of ERBB2 signaling
- ESR-mediated signaling
- Extra-nuclear estrogen signaling
- RHOBTB2 GTPase cycle
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Constitutive Signaling by Overexpressed ERBB2
- Aggrephagy
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
- Potential therapeutics for SARS
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Assembly and release of respiratory syncytial virus (RSV) virions
- Respiratory syncytial virus genome replication
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- Quercetin
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- Tanespimycin
- SNX-5422
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- CCT-018159
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
- Copper
- Polaprezinc
- Alvespimycin
|
|
|
HSP90B1 |
heat shock protein 90 beta family member 1 |
- Trafficking and processing of endosomal TLR
- Scavenging by Class A Receptors
- Scavenging by Class A Receptors
- ATF6 (ATF6-alpha) activates chaperone genes
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Interleukin-4 and Interleukin-13 signaling
- Post-translational protein phosphorylation
|
- Rifabutin
- 2-Chlorodideoxyadenosine
- Geldanamycin
- Diglyme
- N-Ethyl-5'-Carboxamido Adenosine
- Radicicol
- METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE
- 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE
- Copper
|
|
|
ITGB1BP1 |
integrin subunit beta 1 binding protein 1 |
|
|
|
|
KAT5 |
lysine acetyltransferase 5 |
- Formation of the beta-catenin:TCF transactivating complex
- Formation of the beta-catenin:TCF transactivating complex
- DNA Damage/Telomere Stress Induced Senescence
- HATs acetylate histones
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Sensing of DNA Double Strand Breaks
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Estrogen-dependent gene expression
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- Cardiogenesis
|
- Coenzyme A
- S-Acetyl-Cysteine
|
|